THU0452 Secondary Hemophagocytic Lymphohistiocytosis: A Series of 11 Patients. Literature Review
Autor: | C.A. Egües Dubuc, I. Hernando Rubio, C. Meneses Villalba, V. Aldasoro Cáceres, M. Ecenarro Uriarte, J. Belzunegui Otano |
---|---|
Rok vydání: | 2013 |
Předmět: |
Secondary Hemophagocytic Lymphohistiocytosis
medicine.medical_specialty Pediatrics Hemophagocytic lymphohistiocytosis medicine.diagnostic_test biology business.industry Immunology Hepatosplenomegaly medicine.disease biology.organism_classification Intensive care unit General Biochemistry Genetics and Molecular Biology Surgery law.invention Rheumatology law Macrophage activation syndrome Biopsy Etiology Immunology and Allergy Medicine Pneumocystis jirovecii medicine.symptom business |
Zdroj: | Annals of the Rheumatic Diseases. 72:A317.2-A317 |
ISSN: | 1468-2060 0003-4967 |
DOI: | 10.1136/annrheumdis-2013-eular.980 |
Popis: | Background Hemophagocytic Lymphohistiocytosis (HLH) is a severe and acute inflammatory syndrome, underdiagnosed, difficult to treat and can occur at any stage of life. The macrophage activation syndrome is a variant of secondary HLH occurs in autoimmune diseases.1 Objectives Describe the clinical, laboratory, treatment and outcome of patients diagnosed with secondary HLH, identifying probable etiological and triggers causes. Methods A retrospective study was performed between 2008 and 2012 at the Donostia University Hospital, Spain. Inclusion criteria were to met diagnostic criteria for HLH and had a bone marrow biopsy with hemophagocytics cells. Mains endpoints were: demographics, diagnostic criteria, probable etiology, triggers causes and treatments. Secondary endpoints were: time delay in diagnosis, days of hospitalization, need for admission to the Intensive Care Unit (I.C.U.) and the cause, and overall mortality. Results We recruited 11 patients (7 men and 4 women) with a mean age of 48.9 years (16 - 78 years). The below table describes the probable etiologies and triggers of secondary HLH. As no data in the literature described, we found as etiologies and triggers causes of secondary HLH: Campylobacter jejuni in a previously healthy patient without comorbidities; Pneumocystis jirovecii in a patient with Human immunodeficiency virus (H.I.V.); and patient with grade IV glioblastoma multiforme after starting chemotherapy with temozolomide. Hemophagocytics cells were found in ascitic fluid in one patient with Adult Still´s Disease. The mean delay in diagnosis was 14.5 days (3 – 31 days) and average time of hospitalization was 46.7 days (10 – 130 days). The 45% of patient required admission in I.C.U, the leading cause was the multiple organ failure (MOF). The overall mortality rate was 36.4% (4 MOF and 1 massive hemoptysis). Treatment given was steroids, synthetic immunosuppressants and biological drugs. Conclusions The secondary HLH should be suspected in any patient with prolonged fever unresponsive to broad-spectrum antibiotics, hepatosplenomegaly, cytopenias, coagulation and liver disorders. Hemophagocytics cells might be found in pathological body fluids before a bone marrow biopsy had been done or when there are doubts in the result of it. Meet all the diagnostic criteria is not necessary to start treatment when you have a high clinical suspicion and a bone marrow biopsy with hemophagocytics cells. Mortality can be influenced by etiology, trigger cause, and diagnosis and treatment delay. References Henter JI, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48:124. Disclosure of Interest None Declared |
Databáze: | OpenAIRE |
Externí odkaz: |